[ad_1]
Receive instant alerts when news about your actions unfolds. Claim your free 2 week trial at StreetInsider Premium right here.
UNITED STATES
SECURITY AND EXCHANGE COMMITTEE
Washington, DC 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
UNDER RULES 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT
1934
For the month of November 2018
Commission file No 001-38496
Canopy Growth Corporation
1 Hershey Drive
Smith Falls, Ontario
K7A 0A8
Indicate by check if the files of the applicant
or file annual returns on Form 20-F or Form 40-F.
Form 20-F ☐
Form 40-F ☒
Indicate by checkmark if the registrant submits
Form 6-K on paper, pursuant to Rule 101 (b) (1) of the S-T Regulation:
Yes ☐ No ☒
Indicate by checkmark if the registrant submits
Form 6-K on paper, pursuant to Rule 101 (b) (7) of the S-T Regulation:
Yes ☐ No ☒
Indicate by checkmark if the declarant by providing
the information contained in this form also provides information to the Commission in accordance with Rule 12g3-2 (b) of
the Securities Exchange Act of 1934.
Yes ☐ No ☒
INDEX OF EXHIBITION
1
SIGNATURES
In accordance with the requirements of the securities exchange
Act of 1934, the holder duly signed this report on his behalf by the undersigned, duly authorized for this purpose.
| Canopy Growth Corporation | ||
| By: |
/ s / Bruce Linton |
|
| First name: | Bruce Linton | |
| Title: | General manager | |
Date: November 23, 2018
2
Exhibit 99.1
A professor of cannabis science announced
to study the role of cannabis in the treatment of opioid overdose
VANCOUVER, Nov. 23, 2018 / CNW / – Examination
the potential of cannabis to cope with the opioid overdose crisis and other substance use-related disorders is a top priority for Dr.
M-J Milloy, a recognized leader in the field of epidemiology and the first cannabis science professor in the UK for canopy growth
from British Columbia. Initially, this Chair will lead clinical trials to explore the role that cannabis can play in helping people
with opioid consumption disorder remains on their treatment plan.
In the first nine months of 2018, it is estimated
1,143 people died from an alleged overdose of opioids in British Columbia.
"We need everyone to save lives
and help people find the long-term treatment and recovery services they need, "said Judy Darcy, Minister of
Mental health and addictions. "Our government has been bold and innovative in proposing treatment options – based on
evidence – for people living with addiction. This chair, the first of its kind, will lead research and clinical trials.
how cannabis products can be used to address the overdose crisis, resulting in the deaths of three to four people a day. "
Dr. Milloy is a researcher at the British
Columbia Addiction Center (BCCSU). Epidemiologist of drug addiction, his research focused on interrelations
between illicit drugs and HIV, and the impact of cannabis regulation on public health and the medical application of cannabis
and cannabinoids, particularly for people living with HIV or suffering from substance use disorders.
Research shows that less than a third of
people who start treatment with opioid agonists (OAT), methadone or buprenorphine / naloxone, continue their treatment after six months.
Abandonment of drug treatment is a serious risk factor for overdose deaths. The results of these clinical trials could help
identify ways to better support people with opioid use disorder through cannabis-based therapy.
Dr. Milloy's research will contribute to
New evidence suggests that cannabis can have a positive impact on the well-being of people suffering from opioid use disorder.
This chair was created by
funding from Canopy Growth and the Province of British Columbia. Province invested $ 500,000 in BCCSU to support research
leading to solutions to the overdose crisis. Canopy Growth Provides $ 2.5 Million to UBC and BCCSU to Create Faculty
and create a lasting legacy of research through the Canabis Growth Cannabis Science Endowment Fund.
Fast facts:
- Dr. Milloy's recent research
includes studies that found: - Use cannabis every day
linked to a lower risk of starting to inject drugs among street youth - Cannabis daily intake increased
likelihood that people stay on OAT treatment - Intentional use of cannabis
resulted in an earlier decline in crack consumption among crack consumers - Dr. Milloy is the author
more than 150 peer-reviewed articles on the impact of policies on outcomes for the health of drug users.
citations
Dr. Dermot Kelleher, Dean of the Faculty of Medicine
And Vice President, Health at UBC –
"The opioid overdose crisis requires a holistic approach
and scientific approaches to develop new knowledge and strategies in response to this urgent health problem facing our society.
Cannabis Growth's new Cannabis Growth professor promises to generate much-needed, evidence-based solutions that:
improve the health and well-being of British Columbians. "
Dr. Mark Ware, Director of Canopy Growth Chief Medical
Officer –
"There is a clear need for
resources, as well as innovative leadership in collaborating with industry, government, and academia to address the overdose crisis
continues to have a devastating impact on families and communities across Canada. Today we recognize the lived experience of
affected and proudly support this milestone in building a legacy of medical cannabis research with a positive goal:
impact on people with substance use disorders around the world. Dr. Milloy is a passionate and dedicated scientist who focuses on
research that has a real impact, and we are delighted that UBC has chosen him as a Canopy Growth professor in the science of cannabis. "
Dr. M-J Milloy, Professor of Canopy Growth
Cannabis science –
"The therapeutic benefits of cannabis
are just beginning to be understood. Early research has shown that this could have a stabilizing impact on people with opioids
use disorders, improve their quality of life and offer a path to long-term treatment solutions. In the middle of an overdose
In a crisis situation, we have a scientific imperative from this research. I am grateful for the support of Canopy Growth and the province
of British Columbia and their commitment to investing in evidence-based solutions to this urgent health crisis. "
Photos: for the photos of the event following the
announcement, please visit: https://www.flickr.com/photos/bcgovphotos/
About Canopy Growth Corporation
Canopy Growth is one of the world's leading cannabis and hemp companies, offering distinct brands and preserved varieties of cannabis.
in the form of dried capsule, oil and capsule. From product and process innovation to market execution, Canopy Growth is based on
passion for leadership and commitment to building a world class cannabis company, product, site and country at a time. the
The company is present in 12 countries on five continents. The company is proudly dedicated to training health practitioners,
conducting extensive clinical research and understanding of cannabis to the general public, and through its wholly-owned subsidiary,
Canopy Health Innovations has dedicated millions of dollars to cutting-edge, marketable research and development of intellectual property. Through
Canopy Rivers Corporation, a partially owned subsidiary of the company, provides resources and investments to newcomers to the market and
build a portfolio of stable investments in the sector. From our historical public listing on the Toronto Stock Exchange and New
The York Stock Exchange continued its international expansion, its pride in advancing shareholder value through leadership is rooted
in everything we do at Canopy Growth. Canopy Growth has established partnerships with industry leaders, including the cannabis icon Snoop.
Dogg, legends of the DNA Genetics and Green House cross, and the Fortune 500 alcohol leader, Constellation Brands, to name a few.
Canopy Growth operates 10 licensed cannabis production sites with a production capacity of more than 4.3 million square feet, including:
over 500,000 square feet of GMP certified production space. For more information, visit www.canopygrowth.com
Notice Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the US Private Securities Litigation.
1995 Reform Act and "forward-looking information" within the meaning of applicable Canadian securities legislation.
Often, but not always, forward-looking statements and information can be identified using terms such as "plans",
"wait" or "do not expect", "expect", "estimate", "intend", "anticipate"
or "does not anticipate", or "believes", or variations of those words and phrases or declares that certain actions,
events or results "may", "could", "would", "could" or "will" be taken, will occur
or be reached. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors that
result in material differences between the actual results, performance or achievements of Canopy Growth and its subsidiaries.
any future results, performance or achievements expressed or implied in the forward-looking statements or information contained therein
in this press release. Examples of such statements include statements about medical research initiatives and partnerships.
The risks, uncertainties and other factors involved in the forward-looking information could lead to events, results, performance, etc.
perspectives and possibilities of differing materially from those expressed or implied by this forward-looking information, including
the ability of the company to meet provincial sales contracts or the provinces purchasing all the cannabis assigned to them, and these risks
in the Company's Annual Information Form dated June 28, 2017 and filed with the Canadian securities regulatory authorities available
on the company profile on SEDAR at www.sedar.com. Although the company believes that the assumptions and factors used
in preparing the forward-looking information or forward-looking statements contained in this press release are reasonable and based on undue reliance.
should not be placed on such information and no assurance can be given that such events will occur within the time periods indicated
or at all. The forward-looking information and forward-looking statements included in this press release are made as of
of this press release and the Company assumes no obligation to publicly update such forward-looking information or forward-looking information.
the information must reflect new information, subsequent events or otherwise, except as required by applicable securities laws.
SOURCE Canopy Growth Corporation
See original content: http://www.newswire.ca/en/releases/archive/November2018/23/c3974.html
% CIK: 0001737927
For more information: Media Contact: Ministry of Mental
Health and Addictions Communications, 778-587-3237 (media line); BC Addiction Center, [email protected],
778-918-1537; Contact: Aly-Khan Virani, [email protected], 236-688-5123; Investor Relations, Tyler Burns, [email protected],
855-558-9333 ext. 122; Director: Bruce Linton, [email protected]
CO: Canopy Growth Corporation
CNW 15: 30e 23-NOV-18
[ad_2]
Source link
